Together, cancer meets its match
Omico is changing the way we fight cancer by accelerating access to precision oncology. We are a national, independent, not-for-profit organisation, uniting Australia’s world-class cancer institutes, researchers, clinicians, industry partners and government like never before. By leveraging a nationwide network of expertise and resources, we aim to improve outcomes for all Australian cancer patients. With fast-tracked molecular and genomic screening, biomarker-led trial set up and patient enrolment from the entire nation, we’re accelerating access to next generation treatments and preventive strategies.
What we do
We aim to improve outcomes for Australians living with cancers, by:
- Increasing access to genomic profiling to detect unique genetic variations in cancer patients’ tumours to identify potential matches to new targeted treatments options
- Growing and streamlining biomarker-led clinical trials by expediting patient recruitment and site setup, and attracting more international trials to Australia, facilitating faster transitions from discovery to clinical application
- Advancing a research-led model of care as to open new treatment pathways for patients, and supporting drug development and cancer research through the collection of real-world data
How our molecular screening works
If you or someone you know has advanced, incurable or an earlier diagnosis of a poor prognosis cancer or is at high-risk for cancer (due to hereditary conditions) then:
- Your doctor completes an online referral form
- You sign a consent form
- Omico assesses the genes and other molecules in your cancer tissue
- Our experts match results to an existing therapy or clinical trial of a new drug
- Process takes 8 to 10 weeks
Researchers
Meet intellectually-stimulating research that changes cancer care and transforms lives.
Clinicians
Meet accelerated access to innovative new therapies for your patients.
Government
Meet an opportunity to advance the nation’s health and wealth.
Advocacy Groups
Meet a partner that can help you make a real difference for those affected by cancer.
Who we work with
Recent news
Tessellate BIO, Omico and CMRI announce a multi-year collaboration to accelerate discovery of synthetic lethal precision therapies to address ‘ALT’ cancers
National, not for profit genomic pioneer, Omico, welcomes the formal announcement of a unique collaboration with Tessellate BIO and CMRI (Children’s Medical Research Institute) which focusses on advancing the understanding of alternative lengthening of telomeres (ALT), a mechanism present in cancer cells, and accelerating the development of precision medicines to target it.
First of its kind educational cancer and genomics initiative commences for the community
This week, not-for- profit genomics pioneer, Omico, commences a first-of-its kind national educational initiative to provide Australians with advanced, incurable or poor prognosis cancers an increased understanding of the power of comprehensive genomic profiling (CGP) and precision oncology as a genuine component of an advanced cancer management plan.
‘No time to waste, no more lives to lose’ says genomics pioneer. A bold and innovative approach is needed to fight cancer
Addressing the National Press Club on Rare Cancers Awareness Day (26 June), Prof Thomas will call for a bolder approach to harnessing rapid advances in cancer innovation known as ‘precision oncology’. For Australians with the challenging diagnosis of rare, advanced or incurable cancers he wants the words ‘it’s time to get your affairs in order and prepare your family’ to be replaced with an immediate directive to the genomics tools now available – genomic profiling of the cancer and matching to precision medicines.